Sage Journals: Discover world-class research

Abstract

Around 40—70% patients with treatment-resistant schizophrenia fail to respond to clozapine. Though combining antipsychotics is commonly practised with non-responders, there is Little evidence for its use.

We carried out a retrospective review of case notes of patients with treatment-resistant schizophrenia on clozapine—aripiprazole combination at our clozapine clinic. We report changes in psychotic symptoms, social function, weight, total cholesterol, serum glucose, HDL, CGI and GAF score pre- and post-aripiprazole augmentation.

Clozapine—aripiprazole combination was associated with 22% reduction of clozapine dose. Eighteen out of 24 (75%) Lost a mean weight of 5.05 kg. There was improvement in positive and negative symptoms, sociaL functions, weight Loss and a moderate increase in HDL. Our findings suggest that clozapine—aripiprazole is a safe and tolerable combination; however, controL trials are needed to validate our findings.

Keywords

treatment resistant schizophrenia clozapine aripiprazole augmentation weight

Get full access to this article

View all access options for this article.

References

American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorder (4th edn) (DSM-IV). Washington, DC: APA

Barnes T R E , Dursun S. (2005) Treatment resistance in schizophrenia . Psychiatry 4: 68—70

Bolonna A.A. , Kerwin R.W. (2005) Partial agonism and schizophrenia . Br J Psychiatry 186: 7—10

Buckland P.R. , Hoogendoorn B. , Guy C.A. , Smith S.K. , Coleman S.L. , O'Donovan M.C. (2005) Low gene expression conferred by association of an allele of 5-HT2C receptor gene with antipsychotic-induced weight gain . Am J Psychiatry 162: 613—615

Conley R.R. , Kelly D.L. (2001) Management of treatment resistance in schizophrenia . Biol Psychiatry 50: 898—911

Faycal M. , Constantin T. , Raphael G. , Marie-France P. , Saida D. , Jean-Pierre O , Henri L. , David G. (2006) Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrena . Clin Neuropharmacol 29: 28—33

Gupta S. , Masand P. (2004) Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders . Ann Clin Psychiatry 16: 155—166

Guy W. ( 1976) Clinical Global impression (CGI): ECDEU Assessment Manual for Psychopharmacology (revised). US Department of Health, Education and Welfare, Rockville, MD

Jordan S. , Koprivica V. , Chen R. , Tottori K. , Kikuchi T. , Altar C.A. (2002) The antipsychotic aripiprazole is potent, partial agonist at the human 5-HT1A receptor . Eur J Pharmacol 441: 137—140

10.

Kane J. , Honigfeld G. , Singer J. , Meltzer H. , Clozaril Collaboration Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double blind comparison with chlorpromazine . Arch Gen Psychiatry 45: 789—796

11.

Kontaxakis V.P. , Ferentinos P.P. , Havaki-Kontaxaki B.J. , Roukas D.K. (2005) Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review . Eur Psychiatry 20: 409—415

12.

Lieberman J.A. , Safferman A.Z. , Pollack S. , Szymanski S. , John C. , Howard A. , Kronig M. , Bookstein P. , Kane J.M. (1994) Clinical effect of clozapine in chronic schizophrenia: response to treatment and predictors of outcome . Am J Psychiatry 151: 1744—1752

13.

Lim S. , Pralea C. , Schnitt J. , Bowers M.B. , Cooper C Jr (2004) Possible increased efficacy of low-dose clozapine when combined with aripiprazole . J Clin Psychiatry 65: 1284—1285

14.

Marder S.R. , Jody D. , Kaplita S. , Saha A.R. , Carson Jr WH , Torbeyns A. , Stock E.G. (2003) Glycemic control and plasma lipids in long-term treatment with aripiprazole . Presented at the 2003 APA Annual meeting, 17—22 May 2003; San Francisco, CA

15.

Reynolds G.P. , Zhang Z. , Zhang X. (2002) Association of antipsychotic drug induced weight gain with a 5-HT2C-receptor gene polymorphism . Lancet 359: 2086—2087

16.

Tecott L. , Sun L. , Akana S. (1995) Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors . Nature 374: 542—546

17.

Tighe S. , Dinan T. (2005) An overview of the central control of weight regulation and the effect of antpsychotic medication . J Psychopharm 19(6) (suppl.): 36—46

18.

Ziegenbein M. , Sieberer M. , Calliess I.T. , Kropp S. (2005) Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia . Aust N Z J Psychiatry 39: 840—841

19.

Remington G. , Saha A. , Chong S. , Shammi C. (2005) Augmentation strategies in clozapine-resistant schizophrenia . CNS drugs 19: 843—872

20.

Yuan X. , Yamada K. , Ishiyama-Shigemoto S. , Koyama W. , Nonaka K. (2000) Identification of polymorphic loci in the promoter region of the serotonin 5HT2C receptor gene and their association with obesity and type II diabetes . Diabetologia 43: 373—376

Is clozapine—aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?

Abstract

Keywords

Get full access to this article

References